Compare The Coca-Cola Co K (KO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Merck & Co., Inc. — how do they compare? The Coca-Cola Co K trades at $82.02 (market cap $353.32B), while Merck & Co., Inc. trades at $125.97 (market cap $307.25B). The key difference: The Coca-Cola Co K and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| KO | MRK | |
|---|---|---|
Market Cap | $353.32B | $307.25B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $129.52 |
52-Week Low | $65.67 | $77.60 |
Enterprise Value | $383.39B | $350.66B |
Dividend Yield | 2.58% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.97, up 0.5% today, with a bullish analyst consensus and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.86 beating expectations, and robust profitability metrics including a 27.8% net income margin. Technical indicators are mixed, with moving averages bullish but oscillators neutral. Recent news highlights institutional buying and stable demand trends, though regional divergences exist.
The outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include macroeconomic headwinds and competitive pressures, but the company's dividend history and strong cash flow support long-term stability. Earnings growth and institutional confidence are key catalysts for further appreciation.
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
